INmune Bio's MINDFuL Trial Featured at AD/PD 2026 as Successful Example of Precision Approach to Clinical Trials Targeting Inflammation in Early Alzheimer's Disease.

Thursday, Mar 19, 2026 8:02 am ET1min read
INMB--

INmune Bio's MINDFuL trial was featured at AD/PD 2026 as a successful example of targeting inflammation in early Alzheimer's disease. The trial's biomarker enrichment strategy aligned with the mechanism of action, identifying patients most likely to respond. Dr. Malú Gámez Tansey, a neurology professor, highlighted the trial as a blueprint for Alzheimer's drug development. INmune Bio is advancing a Phase 2b/3 registrational program for XPro1595 in enriched early Alzheimer's patients.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet